실적분석 2026년 8월 3일

Stoke Therapeutics (STOK) Q2 2026 Earnings Analysis — Revenue Beat and Phase 3 Enrollment Complete, but Loss Widens

Earnings Scorecard

Revenue: $9.3 million (about -33% year over year vs. $5.09 million estimate) ✅ Beat

EPS (earnings per share): GAAP loss per share -$0.93 (consensus adjusted -$0.78 — different bases, not directly comparable)

Guidance: Not provided (no revenue or EPS outlook; noted cash of about $420 million is sufficient to fund operations through a potential U.S. launch in early 2028)

Stock reaction: After-hours -5.45% ($27.95) — as of 06:11 Korea time on 08-04

Positives

Revenue beat: Q2 revenue of $9.3 million well above the $5.09 million estimate

Phase 3 enrollment complete: EMPEROR study enrolled 162 patients, with no treatment discontinuations

Cash runway: About $420 million, sufficient to fund operations through a potential U.S. launch in early 2028

Stoke Therapeutics is a biotechnology company developing ribonucleic acid medicines that restore protein expression, and its lead candidate zorevunersen is a potential disease-modifying treatment for Dravet syndrome. The Q2 revenue of $9.3 million came from the recognition of amounts under collaboration and license agreements with Acadia and Biogen, down from $13.8 million a year earlier but well above the $5.09 million analyst estimate.

On the clinical side, enrollment of the 162-patient primary analysis population for the U.S. New Drug Application in the Phase 3 EMPEROR study, which spans the U.S., U.K., and Japan, was completed in June 2026, and as of July 31, 2026, there had been no treatment discontinuations. Cash, cash equivalents, and marketable securities stood at $354.3 million at quarter-end, and adding the $65.7 million in net proceeds from a subsequent at-the-market (ATM) offering brings the total to about $420 million, which the company said is sufficient to fund operations through a potential U.S. commercialization of zorevunersen in early 2028.

Negatives

Widening loss: Q2 net loss of $61.6 million, loss per share of $0.93

Sharp cost increase: R&D expense of $49.5 million and SG&A expense of $25.3 million, both up significantly year over year

Data gap: Phase 3 pivotal data readout not expected until Q3 2027, limiting near-term catalysts

As is typical for a clinical-stage biotech, revenue is driven by collaboration recognition rather than product sales, and the year-over-year decline in revenue and the wider loss moved in tandem. R&D expense rose from $25.9 million to $49.5 million due to activity and personnel costs tied to zorevunersen progress, while SG&A expense climbed from $15.3 million to $25.3 million on launch preparation and headcount expansion. As a result, net loss widened from $23.5 million ($0.40 per share) a year earlier to $61.6 million ($0.93 per share). The reported figures are on a GAAP basis, and because the accounting basis differs from the consensus adjusted loss per share of $0.78, it is difficult to declare one superior.

The key data for the investment thesis, the Phase 3 pivotal efficacy and safety readout, is not expected until Q3 2027, and completion of the rolling U.S. New Drug Application submission is slated for the second half of 2027. The completed enrollment and schedule guidance may already be largely priced in, and the increase in share count from a single-investor at-the-market offering after quarter-end could also be read as a dilution overhang.

What Management Said

CEO Ian F. Smith highlighted the rapid 162-patient Phase 3 enrollment and passage of key study milestones as progress across the business this year, and stressed that there have been no treatment discontinuations in EMPEROR and that the 4-year safety and efficacy data from the ongoing open-label extension study provide support. He reaffirmed the roadmap of holding a Type B pre-New Drug Application meeting with the U.S. Food and Drug Administration in the second half of 2026 to align on data package, schedule, and statistical analysis plan, then initiating the rolling U.S. New Drug Application in Q1 2027.

On the pipeline, he mentioned Phase 1 OSPREY dose escalation in autosomal dominant optic atrophy with initial data expected in the first half of 2027, expansion of early research in haploinsufficiency diseases, and the addition of a new Chief Scientific Officer. No revenue or EPS guidance was provided, with the emphasis placed on the cash runway of about $420 million to fund operations through a potential U.S. launch in early 2028.

Market Reaction and What to Watch Next

The after-hours weakness is more naturally read as a reflection of the wider loss tied to the surge in R&D and SG&A expense, and of a catalyst gap of more than a year until the pivotal readout, rather than the revenue beat. The completed enrollment, pre-New Drug Application meeting, and rolling submission timeline are largely already known milestones, and on a quarterly update with no new efficacy figures the market appears to have tilted toward "digesting" the news. Dilution from the at-the-market offering after quarter-end may also have weighed on near-term supply-demand dynamics.

Monitor outcomes of the second-half 2026 U.S. Food and Drug Administration pre-New Drug Application meeting and whether agreement is reached on the data package and statistical plan

Track progress of EMPEROR patients through the 52-week treatment period and watch for any treatment discontinuations or safety signals

Watch whether the timeline holds for initial Phase 1 OSPREY data in the first half of 2027 and Phase 3 pivotal data in Q3 2027